Impact of partial bivalent HPV vaccination on vaccine-type infection: A population-based analysis

British Journal of Cancer

Volumn 114, Issue 11, 2016, Pages 1261-1264

  Cuschieri, K ^a,b   Kavanagh, K ^c   Moore, C ^a   Bhatia, R ^b   Love, J ^d   Pollock, K G ^d  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d HEALTH PROTECTION SCOTLAND   (United Kingdom)

Author keywords

bivalent; epidemiology; HPV; impact; prevalence; vaccine

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CROSS PROTECTION; DRUG EFFICACY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; UTERINE CERVIX CYTOLOGY; VACCINATION; AGE; CROSS REACTION; DOSE RESPONSE; HEALTH SURVEY; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; PREVENTIVE HEALTH SERVICE; SCOTLAND; SECONDARY IMMUNIZATION; UTERINE CERVIX; VACCINE IMMUNOGENICITY; VAGINA SMEAR; VIROLOGY;

ADOLESCENT; AGE FACTORS; CERVIX UTERI; CROSS REACTIONS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 31; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOGENICITY, VACCINE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POPULATION SURVEILLANCE; PREVALENCE; SCOTLAND; VACCINATION; VAGINAL SMEARS;

EID: 84971325196     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.97     Document Type: Article

References (13)

1. Bhatia R, Kavanagh K, Cubie H, Serrano I, Wennington H, Hopkins M, Pan J, Pollock KG, Palmer TJ, Cuschieri K (2016) Use of HPV testing for cervical screening in vaccinated women-insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study. Int J Cancer; e-pub ahead of print 4 Feb 2016; doi:10.1002/ijc.30030.
2. Brotherton JM, Malloy M, Budd AC, Saville M, Drennan KT, Gertig DM (2015) Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia. Papillomavirus Res 1: 59-73.
3. Drolet M, Benard E , Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JM, Cummings T, Donovan B, Fairley CK, Flagg EW, Johnson AM, Kahn JA, Kavanagh K, Kjaer SK, Kliewer EV, Lemieux-Mellouki P, Markowitz L, Mboup A, Mesher D, Niccolai L, Oliphant J, Pollock KG, Soldan K, Sonnenberg P, Tabrizi SN, Tanton C, Brisson M (2015) Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-Analysis. Lancet Infect Dis 15: 565-580.
4. Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Donaghy M (2014) Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 110: 2804-2811.
5. Kavanagh K, Sinka K, Cuschieri K, Love J, Potts A, Pollock KG, Cubie H, Donaghy M, Robertson C (2013) Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact. BMC Infect Dis 13: 519.
6. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM. Costa Rica Vaccine Trial and PATRICIA study groups (2015) Efficacy of fewer than three doses of an HPV-16/18 AS04-Adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol 16: 775-786.
7. LaMontagne DS, Mugisha E, Pan Y, Kumakech E, Ssemaganda A, Kemp TJ, Cover J, Pinto LA, Safaeian M (2014) Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda. Vaccine 32: 6303-6311.
8. Lowy DR, Herrero R, Hildesheim A. Participants in the IARC/NCI workshop on Primary Endpoints for Prophylactic HPV Vaccine Trials (2015) Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. Lancet Oncol 16: e226-e233.
9. O'Leary MC, Sinka K, Robertson C, Cuschieri K, Lyman R, Lacey M, Potts A, Cubie HA, Donaghy M (2011) HPV type-specific prevalence using a urine assay inunvaccinated male and female 11-To 18-year olds in Scotland. Br J Cancer 104: 1221-1226.
10. Palmer TJ, McFadden M, Pollock KG, Kavanagh K, Cuschieri K, Cruickshank M, Cotton S, Nicoll S, Robertson C (2016a) HPV immunisation and cervical screening-confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study. Br J Cancer 114: 582-589.
11. Palmer TJ, McFadden M, Pollock KG, Kavanagh K, Cuschieri K, Cruickshank M, Nicoll S, Robertson C (2016b) HPV immunisation and increased uptake of cervical screening in Scottish women; observational study of routinely collected national data. Br J Cancer 114: 576-581.
12. Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Cruickshank M, Palmer TJ, Nicoll S, Donaghy M (2014) Reduction of low-And high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 111: 1824-1830.
13. Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, Quint W, van Doorn LJ, Sherman ME, Xhenseval V, Herrero R, Hildesheim A. Costa Rican Vaccine Trial Group (2010) Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and-18 infections. J Natl Cancer Inst 102: 1653-1662.